Wall Street brokerages forecast that Yumanity Therapeutics, Inc. (NASDAQ:YMTX) will report $2.27 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Yumanity Therapeutics’ earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $3.50 million. The company is expected to issue its next quarterly earnings results on Thursday, August 5th.
According to Zacks, analysts expect that Yumanity Therapeutics will report full-year sales of $10.08 million for the current fiscal year, with estimates ranging from $6.50 million to $14.03 million. For the next fiscal year, analysts forecast that the firm will report sales of $9.56 million, with estimates ranging from $4.00 million to $14.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Yumanity Therapeutics.
Yumanity Therapeutics (NASDAQ:YMTX) last issued its quarterly earnings results on Thursday, May 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.01). The firm had revenue of $3.53 million during the quarter, compared to the consensus estimate of $1.00 million.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Ikarian Capital LLC lifted its stake in Yumanity Therapeutics by 65.6% during the first quarter. Ikarian Capital LLC now owns 219,470 shares of the company’s stock worth $3,972,000 after purchasing an additional 86,956 shares during the period. Artal Group S.A. bought a new position in Yumanity Therapeutics during the fourth quarter worth about $3,696,000. Sphera Funds Management LTD. lifted its stake in Yumanity Therapeutics by 59.9% during the first quarter. Sphera Funds Management LTD. now owns 208,609 shares of the company’s stock worth $3,776,000 after purchasing an additional 78,175 shares during the period. Stonepine Capital Management LLC bought a new position in Yumanity Therapeutics during the fourth quarter worth about $1,850,000. Finally, Pura Vida Investments LLC bought a new position in shares of Yumanity Therapeutics in the first quarter valued at approximately $1,246,000.
YMTX stock traded up $0.25 during trading on Tuesday, reaching $16.08. 100 shares of the stock were exchanged, compared to its average volume of 73,876. Yumanity Therapeutics has a twelve month low of $13.52 and a twelve month high of $36.80. The firm has a market capitalization of $164.06 million, a P/E ratio of -0.73 and a beta of 0.73. The business’s 50 day simple moving average is $16.20. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.61 and a quick ratio of 3.61.
Yumanity Therapeutics Company Profile
Yumanity Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases.
Further Reading: Cost of Equity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Yumanity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yumanity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.